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Neonatal Cholestatic Liver Diseases
Cholestatic liver disease in children occurs as a result of
either an alteration in hepatocyte bile formation or dis-
ruption of bile flow out of the hepatocyte through intra-
hepatic bile ductules or extrahepatic bile ducts [1]. Liver
disease usually appears within the first few weeks follow-
ing birth. A large number of disorders exhibit cholestatic
jaundice in neonatal life including (a) numerous cholan-
giopathies, such as extrahepatic biliary atresia, cystic fibro-
sis (CF), choledochal cyst, alpha1-Antitrypsin deficiency
and Alagille's syndrome, (b) several abnormalities of the
gall bladder, such as cholelithiasis and cholecystitis, and
(c) bile acid transport disorders. The most commonly
occurring form of neonatal cholestasis is biliary atresia,
representing a relative frequency of approximately 30%
[1]. In order to administer effective therapeutic interven-
tion early diagnosis is critical. This can prove difficult as a
number of phenotypic manifestations of the many differ-
ent forms of neonatal cholestasis are similar and may even
overlap.
Role of Hepatic Stellate Cells
If left untreated cholestatic liver injury results in the devel-
opment of hepatic fibrosis and ultimately may progress to
cirrhosis. The precise pathophysiological mechanisms
responsible for hepatic fibrogenesis in pediatric choles-
tatic liver disease are unknown. Hepatic stellate cells have
been shown to be responsible for increased production of
fibrillar collagens in a number of adult liver diseases and
in experimental models of liver injury. Recent studies by
our group have identified stellate cells as the principal
source of type I collagen in neonatal cholestatic liver dis-
eases such as biliary atresia [2] and in the focal biliary cir-
rhosis associated with CF [3]. In these studies, large
numbers of myofibroblast-like cells were demonstrated in
the extracellular matrix surrounding expanded bile ducts
and within fibrosis septa bridging between portal tracts
(2). Activated hepatic stellate cells, demonstrated by the
expression of α-smooth muscle actin and their stellate
morphology, were particularly evident at the interface
between scar and normal tissue [2,3]. This growing mar-
gin of scar tissue formation appeared to be the site of max-
imal stellate cell activation and type I collagen mRNA
expression, although some evidence of collagen gene
expression was also seen in myofibroblast-like cells
within established fibrous septa. This clearly suggests a
role for hepatic stellate cells in the deposition of fibrillar
collagens as the scar expands with continued cholestatic
liver injury. Whether the myofibroblast-like cells which
surround expanded bile ducts within the fibrotic septa are
derived from activated hepatic stellate cells or portal
fibroblasts remains unclear.
Mediators of Fibrogenesis
The precise mechanisms responsible for the activation of
hepatic stellate cells and the subsequent development of
hepatic fibrosis in pediatric cholestatic liver disease are
not known. Bile duct hyperplasia appears to be an early
event in the pathology of both biliary atresia and CF liver
disease. It has been suggested that the biliary hyperplasia
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seen in bile duct-ligated rats may be due to either
increased intraductal pressure [4] or circulating cholangi-
otrophic factors [5]. Hepatic cell injury is suggested as a
potential cause of fibrogenesis in cholestatic liver disease.
This may be due to an increase in the levels of glycine-con-
jugated hydrophobic bile acids which occurs in response
to biliary obstruction and decreased hydration of bile [6].
It has also been suggested that cholestatic hepatotoxicity
may be induced via the depletion of hepatic antioxidants,
such as vitamin E or glutathione [7]. Thus, hydrophobic
bile acid-induced oxidant stress may play a major role in
the viability and function of Kupffer cells, hepatocytes,
bile duct cells and hepatic stellate cells, all of which are
capable of producing cytokines and growth factors which
may drive inflammation and fibrogenesis (Figure 1).
Transforming Growth Factor-beta1 and Matrix 
Production
While the precise mechanisms responsible for initiating
fibrogenesis in pediatric cholestasis are unclear, it is
known that a number of cytokines contribute to the per-
petuation of this process. We have recently demonstrated
that the expression of the profibrogenic cytokine, trans-
forming growth factor-beta 1 (TGF-beta1), is significantly
increased in both biliary atresia [2] and CF liver disease
[3], and is predominantly expressed by bile duct epithelial
cells and also by hepatocytes at the growing margin of the
scar tissue [2,3]. We hypothesize that this TGF-beta1 is
responsible for the transactivation of the procollagen
alpha1(I) gene in both myofibroblast-like cells and acti-
vated hepatic stellate cells in these same areas of scar tis-
sue formation (Figures 1 and 2). The expression of TGF-
beta1 at the scar interface, where maximal fibrogenic activ-
ity occurs in both biliary atresia and CF liver disease,
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suggests both a spatial and temporal association in the
generation of scar tissue in these cholestatic liver diseases.
Indeed, our studies have shown that TGF-beta1 protein
expression in bile duct epithelial cells is significantly cor-
related with the percentage of portal tracts involved in the
histological abnormalities associated with focal biliary
cirrhosis in CF liver disease and that TGF-beta1 mRNA
expression correlates with disease progression [3].
Role of Mitogens and Chemokines
Another key regulator of fibrogenesis is the mitogenic
cytokine, platelet-derived growth factor-BB (PDGF-BB).
The observation of abundant myofibroblast-like cells
within the peri-biliary and scar interface regions of the aci-
nus in both biliary atresia and CF liver disease suggests
either local activation and proliferation of portal fibrob-
lasts or recruitment of stellate cells. Therefore, we hypoth-
esize that bile duct epithelial cells and hepatocytes at the
scar interface produce mitogens and chemokines in
response to biliary obstruction (Figures 1 and 2). There is
recent evidence to support a role for PDGF-BB in choles-
tatic liver injury. In a study using bile duct-ligated rats,
Kinnman and colleagues demonstrated that bile duct cells
express PDGF-BB [8]. Using an in vitro culture system they
showed that hepatic stellate cells are recruited to bile duct
segments by PDGF-BB [8]. While this is an important
observation, the role of PDGF-BB in human neonatal
cholestasis has not been evaluated. Hepatic stellate cells
also respond to numerous other chemokines in vitro, such
as monocyte chemotaxis protein-1 (MCP-1), interleukin-
8, RANTES, endothelin-1 [9] (Figure 1). It is possible that
these chemokines may also play a role in stellate cell
recruitment in cholestatic liver disease (Figure 2). Marra
and colleagues have reported that MCP-1 causes stellate
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cell recruitment in vitro [10] and MCP-1 expression is
increased in cirrhotic adult liver [11]. We propose that
MCP-1 may play a major role in the development of pedi-
atric cholestatic liver injury. In preliminary studies, we
have reported marked hepatic expression of MCP-1 in bil-
iary atresia and CF liver disease, although the role of MCP-
1 in stellate cell recruitment in vivo remains to be deter-
mined [12].
Conclusions
While the precise pathways involved in the initiation of
hepatic fibrogenesis in neonatal cholestasis remain elu-
sive, a number of cytokines and growth factors have been
identified which contribute to the progression of injury
through matrix production and recruitment of inflamma-
tory cells. With this knowledge it may be possible to
develop novel approaches for therapeutic intervention
which could assist in the suppression of fibrogenesis and
may potentially lead to the reduced requirement for liver
transplantation.
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